The FOENIX-MBC2 ongoing clinical trial demonstrated the efficacy of futibatinib in patients with locally advanced/metastatic BC harboring FGFR1/2 amplifications who have experienced disease progression after prior therapy for advanced/metastatic disease (117). This evidence concerns the gene FGFR1 and breast cancer.